恶性血液肿瘤嵌合抗原受体T细胞治疗后耐药与复发研究进展

Progress of chimeric antigen receptor T⁃cell therapy for drug resistance and relapse of hematologic malignancies

嵌合抗原受体T细胞(CAR-T)在恶性血液肿瘤治疗中取得了突破性成果,但耐药与复发限制了其广泛应用。第63届美国血液学会年会上针对CAR-T治疗后耐药与复发的发生机制及应对策略进行了一系列相关报道,对提高CAR-T临床疗效、减少耐药与复发具有重要的指导价值。

Chimeric antigen receptor T⁃cell(CAR⁃T)has made a breakthrough in the treatment of hematologic malignancies,but drug resistance and recurrence have limited its wide application.And at the 63rd annual meeting of the American Society of Hematology,a series of related reports on the mechanism and prevention strategies of drug resistance and recurrence after CAR⁃T therapy were carried out.These reports provide important indications for improving the clinical efficacy of CAR⁃T therapy and reducing relapse.